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Abstract: From the initial characterizations of inflammatory responses in Alzheimer’s disease (AD) affected brains, namely the demon-
stration of activated microglia and reactive astrocytes, complement system activation, increased production of proinflammatory cytoki-
nes, and evidence for microglial-produced neurotoxins, there was hope that reducing inflammation might be a feasible treatment for this 
memory-robbing disease. This hope was supported by a number of epidemiology studies demonstrating that patients who took non-
steroidal anti-inflammatory drugs had significantly lower risk of developing AD. However, clinical trials of anti-inflammatories have not 
shown effectiveness, and in recent years, the concept of immune therapy has become a treatment option as animal studies and clinical tri-
als with A vaccines have demonstrated enhanced amyloid removal through stimulation of microglial phagocytosis. 
This review will examine the current status of whether inhibiting inflammation is a valid therapeutic target for treating AD; what lessons 
have come from the clinical trials; what new pathways and classes of agents are being considered; and how this field of research can pro-
gress towards new therapeutics. We will examine a number of agents that have shown effectiveness in reducing inflammation amongst 
other demonstrated mechanisms of action. The major focus of much AD drug discovery has been in identifying agents that have anti-
amyloid properties; however, a number of these agents were first identified for their anti-inflammatory properties. As drug development 
and clinical testing is a costly and lengthy endeavor, sound justification of new therapeutic targets is required. Possible future directions 
for AD anti-inflammatory or immune clearance therapy will be discussed based on recent experimental data. 
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INTRODUCTION 
  Alzheimer’s disease (AD) represents one of the most serious 
health issues for the elderly. With the aging of the population, par-
ticularly in western societies, the increase in AD is going to be a 
major health-care crisis. For example, in the United States AD cur-
rently affects approximately 4.5 million, but this is predicted to rise 
to 16 million by 2050. Although heart disease and cancer cause 
higher rates of mortality, effective treatments are available for these 
conditions, while this is not the situation for AD. Patients diagnosed 
with AD are currently treated with acetylcholinesterase inhibitors 
(donepezil,rivastigmineorgalantamine),withmemantine,anNMDA 
receptor antagonist, being an additional treatment option for more 
severely-affected AD patients. These agents have been demons-
trated to have a significant effect on slowing the progression of the 
disease, as measured by different psychometric parameters; how-
ever, it is widely accepted that their effectiveness is limited and the 
need for new therapeutic agents is urgent [35,58,144,184]. 
Pathology of AD 
  AD can only be definitively diagnosed by a pathological ex-
amination of the brain postmortem. Histological examination of 
vulnerable brain areas of an AD case (for example, hippocampus, 
entorhinal, temporal, frontal and parietal cortex) with appropriate 
histochemical stains or immunological reagents will identify pro-
fuse numbers of extracellular amyloid beta peptide (A) plaques, 
and also large numbers of neurofibrillary tangles (NFTs). A is 
derived from the pathological processing of the amyloid precursor 
protein (APP) at the -secretase and -secretase sites to produce the 
4 kD A fragments of 40 or 42 amino acids [64,168]. NFTs are 
insoluble structures and represent the remains of the cytoskeleton of 
dead or dying neurons. The insolubility of these structures arise on 
account of the hyperphosphorylation of the microtubule-associated 
protein tau [47]. With the availability about 20 years ago of appro-
priate antibodies that could localize proteins in formaldehyde-fixed 
brain tissues, studies identified the presence of a type of chronic 
microglial inflammatory response in AD brain tissues, especially 
associated with the hallmark plaque and tangle pathological struc-
tures [83,104,116]. Activated microglia were particularly evident 
using antibodies that recognize the class II major histocompatibility 
complex protein HLA-DR. The insolubility and persistence of these  
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pathological structures appears to incite this microglial inflamma-
tory response, though cellular contents of damaged cells also con-
tribute to microglial activation; microglia being a population of 
brain-resident cells with most of the characteristics of macro-
phages/monocytes [178]. The normal function of microglia within 
the brain is immune surveillance; they are the first cell type to re-
spond to any perturbation or injury within the CNS. Although T 
lymphocytes, B lymphocytes and peripheral macrophages have 
been identified in AD brains [49,82,147], it appears that the in-
flammatory response in the brain neuropil is not primarily being 
mediated by these invading peripheral immune cells, but by brain-
resident cells. A major discriminating feature of AD inflammation 
compared to multiple sclerosis is the lack of significant numbers of 
infiltrating leukocytes. As the inflammation in AD is not being 
driven by IFN- [149], it appears to develop and persist in a chronic 
manner. Increased expression by microglia in AD brains of the 
cytokine IL-1 was also initially reported as a feature of microglial 
activation [66]. Other features of an immune response in AD brains 
include activation of the complement system, which has the poten-
tial to further damage neurons and amplify any ongoing inflamma-
tory response. Plaques and tangles in AD brains are immunoreac-
tive for activation fragments of the complement pathway [41, 
114,145]. From these pathological observations, a wide range of 
experimental studies using cultured microglia isolated from rodent 
or human brains demonstrated that A peptide, when in an aggre-
gated, fibril or oligomeric form, could activate microglia to a proin-
flammatory state (reviewed in [178]), which included increased 
production of proinflammatory cytokines, reactive oxygen species, 
degradative proteases and neurotoxic factors [16,54,62,177]. The 
characterization of inflammatory responses in postmortem brain led 
to an “inflammatory hypothesis” for AD, which suggested that the 
inflammatory factors produced in the brain, particularly as a result 
of microglial activation by A, could be causing a loss of healthy 
neurons or damaging axonal processes or synapses. Positron emis-
sion tomography studies of living AD patients with the ligand 
PK11195, which binds to the peripheral benzodiazepine receptor 
and specifically identifies activated microglia, has shown greater 
binding in neocortical areas of brains of AD subjects, even patients 
with early stage AD [21,175]. This is indicative of inflammation 
being an event occurring early in the pathogenesis of the disease 
[21,175]. 
Risk Factors for AD 
  AD is the most common form of dementia, accounting for up to 
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AD, as its incidence is around 1% in the 60-64 year age-group, but 
rising to about 30% in those aged 85 years or older. Associated risk 
factors are head trauma, small brain size, female gender, low educa-
tional status and reduced physical and mental ability in later life 
[20,57,98]. The major genetic risk factor is possession of the apol-
ipoprotein E (apoE) 4 allele [110]. Other risk factors of AD, all of 
which are associated with vascular disease, and some that can be 
affected by possession of the apoE 4, include diabetes, hypercho-
lesterolemia, hypertension, coronary heart disease, obesity, smok-
ing and atherosclerosis [36]. A strong association between cerebral 
atherosclerosis and the development of AD pathology has recently 
been demonstrated [13,23,148]. To date, the only consistent data 
from case-control, cross-sectional epidemiological, and prospective 
incidence studies of subjects concerning what reduces the risk of 
AD were a history of taking NSAIDS (examples [17,18,22,80, 
97,117]). Although some of these earlier studies have limitations 
due to possible selection biases [97], the Baltimore Longitudinal 
Study of Aging, a prospective incidence study, did confirm a re-
duced risk of AD in subjects taking NSAIDS [163]. Similarly, the 
Rotterdam Study of Aging prospective study has demonstrated a 
relative risk of 0.2 (with range 0.05-0.83 at 95% confidence inter-
val) for developing AD in those taking NSAIDS for more than 24 
months [81]. 
  There is no doubt that the pathogenesis of AD is multifactorial 
involving a combination of genetic factors and non-genetic compo-
nents, which together can lead to the generation of toxic processes 
involving dysregulation of amyloid precursor protein metabolism, 
inflammation, oxidative stress, apoptosis, proteosome inhibition, 
mitochondrial dysfunction, imbalances in antioxidant production, 
and glutamate excitotoxicity, amongst others [133]. As such, it 
appears important that new therapeutic agents have multiple targets 
of action that affect a number of these processes. 
Inflammation and AD 
  A comprehensive summary of inflammation and AD was com-
piled about 7 years ago, with the conclusion that inflammation must 
be contributing to AD pathology on account of the many toxic in-
flammatory proteins that are upregulated in AD brains [123]. With 
the apparent lack of effect in clinical trials of tested agents (primar-
ily COX inhibitors) on slowing the progression of mental deteriora-
tion, we should consider whether inflammation is still a relevant 
target for AD. A scheme for how inflammation and A could inter-
act to cause AD pathology is presented in Fig (1). This model 
makes the assumption that the initiating events for neuropathology 
in the brain start in the periphery (i.e. vascular inflammation, athe-
rosclerosis, coronary heart disease) and lead to the initial A depo-
sition; this progression of events is not universally accepted [201]. 
A deposition due to reduced clearance can initiate a cascade of 
events leading to accelerated A oligomerization and aggregation 
that can directly cause synaptic loss and neurodegeneration, and 
ultimately dementia. A is considered by most as the primary driv-
ing force of AD, due to its neurotoxic, oxidative stress and proin-
flammatory effects on multiple cell types. There is evidence that 
cerebral inflammation can lead to increased A production [77]; the 
question that remains to be answered is to what extent inflamma-
tory factors produced in brain directly lead to synaptic damage and 
neurodegeneration; answering this question is central to deciding 
which anti-inflammatory agents should be tested. 
  To be effective, the appropriate anti-inflammatory agent must 
be administered to the appropriate clinical population, who are not 
too far advanced in the disease. If one considers at what stage of the 
disease to administer anti-inflammatory therapeutics, Fig. (2) is 
derived from data from two publications on the relative staging of 
microglia, plaques and NFT in hippocampus and entorhinal cortical 
sections of subjects with progressively increasing clinical dementia 
rating (CDR) scores [170,187]. There is a progressive increase in 
each of these parameters as dementia increases, though both studies 
show a decline in microglia scores as the neuritic plaque progresses 
from stage 3 to 5, or NFT progresses from 5 to terminal stage 6. 
This would indicate that microglia activation could “burn out” at 
the last stages of pathology once mental decline can not be further 
measured. It would appear that at early and moderate stages of AD, 
there is the potential to reduce inflammation, and plaque and tangle 
formation, using drugs that target all features of this pathology. 
Clinical Trials of Anti-Inflammatory Agents with AD Subjects 
  Prospective double-blind placebo-controlled trials are consid-
ered the standard for determining whether an agent is effective for a 
particular disease. A number of trials of anti-inflammatory agents 
have been carried out with AD subjects. The design, dosage, degree 
of severity and inclusion criteria of the patient population was not 
consistent between the trials. The first such trial for AD of a 
NSAID involved a small group of patients treated for 6 months with 
indomethacin or placebo [146]. The indomethacin-treated patients 
Fig. (1). Potential interactions of A peptide, vascular inflammation and cerebral inflammation in precipitating AD pathogenesis. In this scheme, peripheral 
disturbances (e.g. high levels of cholesterol, vascular inflammation, atherosclerosis) lead to compromise/inflammation of the cerebrovasculature. This will 
reduce transport of oxygen and glucose, creating conditions of oxidative stress that can increase A production and aggregation, and neuronal stress directly. 
Deposition of A can lead to cerebral inflammation, which can feedback to increase production of A. The contribution of cerebral inflammation separate 
from A to the progression of pathological changes is unclear, but inflammatory factors can mediate many of the neurotoxic events occurring in AD (tau hy-
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showed no decline in mental function, while the control group de-
clined by 8.4 %. A pilot trial of the NSAID diclofenac in combina-
tion with misoprostol, to provide gastrointestinal protection, in a 
group of mild to moderate AD patients showed no significant dif-
ference in indices of cognitive decline between treated and placebo 
subjects after 25 weeks [155]. A small scale study of the NSAID 
nimesulide, a preferential COX-2 inhibitor, for 24 weeks showed no 
significant differences in rates of cognitive changes [6]. A larger 
scale trial for 1 year of refocoxib, another selective COX2 inhibitor, 
or of naproxen, a non-selective COX inhibitor, versus placebo was 
ineffective at slowing cognitive decline [5]. The lack of effect of 
refecoxib was confirmed in a 1-year trial of mild to moderate AD 
subjects [139]; similarly the anti-inflammatory agent hydroxy-
chloroquine showed no protective effect in preventing decline in 
memory function in a large 18-month trial [171]. A trial of low-
dose prednisone, a potent steroid anti-inflammatory, for 1 year 
showed no difference in cognitive decline between the treated and 
placebo groups [4]. 
  The pronounced dichotomy that has still to be resolved is that 
epidemiological data showing that subjects taking NSAIDs for 
more than 2 years are protected from AD [81,97,117,195], while 
the clinical treatment trials of anti-inflammatories with diagnosed 
AD subjects have generally been negative in preventing cognitive 
decline. It had been hoped that the Alzheimer Disease Anti-Inflam-
matory Prevention Trial on normal elderly with a family history of 
AD would determine whether NSAIDs could prevent or delay the 
onset of AD [118]. However, these will remain unanswered as this 
trial with celecoxib, naproxen, or placebo was terminated before 
completion due to cardiovascular and cerebrovascular side-effects 
from the active drugs, particularly naproxen [1]. 
THERAPEUTIC AGENTS AND TARGETS FOR ALZ-
HEIMER’S DISEASE 
  At the experimental level, new classes of therapeutic agents are 
being examined that have one or several targets in the pathways 
believed to be involved in AD pathogenesis. Agents being tested at 
different levels include those that inhibit the  and secretase 
enzymes, thus preventing A peptide being formed [76,96]; statin 
agents that lower circulating levels of cholesterol, but which also 
have anti-inflammatory properties [38]; agents that inhibit the ag-
gregation of A into toxic oligomers and fibrils [61]; agents that 
inhibit kinases (e.g. glycogen synthase kinase (GSK) 3 and cell 
division cycle kinase (CDC) 25) that are involved in the phosphory-
lation of tau [15]; cytoskeletal modifying agents; thiazolidinedione 
agents used to treat type 2 diabetes; and anti-oxidants and anti-
inflammatory agents [200]. A number of agents being tested for 
effectiveness in AD, for example statins and curcumin have activi-
ties against multiple relevant targets in pathways involved in AD 
pathogenesis. Fig. (3) outlines the properties and pathways that an 
“ideal” AD treatment agent might need to modulate in order to 
modify AD pathogenesis. Data from studies with these different 
types of agents will be discussed to consider why future clinical 
trials of agents with anti-inflammatory properties should focus only 
on those with multiple additional relevant mechanisms of action. 
Inhibition of Cyclooxygenase 
  The majority of the anti-inflammatory agents tested on AD 
patients are prostaglandin H synthase (COX) inhibitors. Although 
some of these agents have other less-well defined modes of actions, 
as trials with these agents have not shown positive results, it might 
indicate that inhibition of the prostaglandin pathways might not be 
a suitable target for retarding the pathogenesis of established AD 
[72]. The role of COX metabolites in AD pathogenesis is still un-
clear. In human brain, COX-2 is primarily localized to neurons, and 
not in activated microglia as would be expected [71,73]. Induction 
of COX-2 immunoreactivity in neurons of AD brains is an early 
event in the disease pathogenesis being maximal at Braak tangle 
stage 0-II before microglial activation is a prominent feature [74], 
but declining as the disease progresses [192]. Measurements of 
COX-2 mRNA in AD brains generally showed increased levels 
associated with pathology [108,130,191]. As some COX metabo-
lites (prostaglandins PGD1 PGD2, PGJ2, and 15d-PGJ2) are agonists 
for PPAR-, activation of which can induce anti-inflammatory 
pathways in macrophages, microglia and astrocytes, inhibition of 
synthesis of proinflammatory PG (e.g. PGE2) will also reduce the 
amounts of anti-inflammatory PG. Similarly, PGE2 has a role in 
neuroprotection; treatment of primary neurons with PGE2 or ago-
nists for the EP-2 and EP-4 PG receptors resulted in significant 
neuroprotection from A toxicity [40], an effect mediated by in-
creased intracellular levels of cyclic AMP. Activation of microglia 
EP2 receptor with PGE2 increased A phagocytosis and reduced the 
microglial-mediated neurotoxicity [159]. Crossing transgenic mice 
overexpressing COX-2 in neurons with a line of A plaque-
developing mice (APPswe/PS1-A246E) resulted in enhanced pro-
duction and deposition of A(40) and A(42) at 24 months [189], 
but not at 12 months [188], although a greater percentage of hippo-
campal neurons from COX2APPswe/PS1-A246E mice showed 
apoptosis in response to A(1-42) than neurons from APPswe/PS1-
A246E mice. Thus, it can be seen that the role of COX and inhibi-
tion of PG synthesis in AD pathology is complex; inhibiting the 
production of PGs with protective/anti-inflammatory properties 
might be more detrimental for chronic AD pathogenic events than 
preventing the effects of proinflammatory PGs. Even though the 
trials with agents that had preferential COX-1 inhibiting activity 
were generally unsuccessful, a role for COX-1 in AD inflammation 
is still possible as COX-1 immunoreactivity is found in microglia in 
AD brains, particularly in microglia associated with amyloid 
plaques [73,193]. 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) 
  Most NSAIDS - aspirin, ibuprofen, indomethacin, sulindac, and 
flurbiprofen - have inhibition of COX as their major mechanism of 
anti-inflammatory activity. These agents, most of which are avail-
able without prescription, have preferential activity in inhibiting 
COX-1, but also have some activity against COX-2, a form of the 
enzyme primarily induced during inflammatory responses. The new 
generations of COX-2 specific inhibitors, which appear effective 
for controlling arthritis, have also been considered as AD therapeu-
tic agents. In recent years, A lowering or aggregation inhibition 
mechanisms of action of NSAIDs have been identified that are not 
Fig. (2). When is the optimal stage of the disease to most effectively treat 
AD with anti-inflammatory agents. Figure shows progression of AD pathol-
ogy, namely that the density of plaques, NFTs and activated microglia in-
crease in the hippocampus/entorhinal cortex with decline in cognitive per-
formance. MMSE – mini-mental status exam; the primary physician screen-
ing test of patient for cognitive decline. CDR – clinical dementia rating; a 
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related to COX inhibition or anti-inflammatory properties. In a 
series of studies, treatment of cultured cells (neural and non-neural) 
with diclofenac, flurbiprofen (R and S and mixed enantiomers), 
ibuprofen, indomethacin, sulindac sulfide and meclofenamic acid 
resulted in lower levels of A(42), but not A(40), production 
[43,181] by modulating secretase activity [14,34]. In order of 
effectiveness at lowering A 1-42 production by H4 cells were 
flurbiprofen, meclofenamic acid, sulindac, fenoprofen, indometha-
cin, diclofenac and ibuprofen [43]. Agents that showed no activity 
in this assay included acetaminophen, aspirin, dapsone, fenbufen, 
ketoprofen, meloxicam and sulindac or sulindac sulfone [43]. The 
effectiveness of flurbiprofen, ibuprofen and sulindac sulfide for 
lowering A production has been confirmed using primary neurons 
as the target cell [56], but this study did not report the specific ef-
fect to A(42) as these agents were effective at lowering A(40) 
production as well. These authors concluded that the mechanism of 
action of these NSAIDs is not related to their COX, lipoxygenase, 
NFB or IB inhibiting-, or PPAR-activating-, properties, as spe-
cific agents for these targets did not affect A levels in the assays 
used [151]. The effect appeared to be due to inhibition of Rho and a 
Rho-kinase [199]. A-lowering activity was also being observed 
using specific Rho-kinase inhibitors, although cells deficient in 
Rho-kinase activity did not demonstrate reduced amounts of A
production. The NSAIDs that demonstrated significant A-
lowering properties in cultured cells were also effective in lowering 
A (1-42) in brains of transgenic Tg2576 mice [43]. By contrast, 
another study that administered indomethacin or the COX-2 inhibi-
tor nimesulide to Tg2576 mice for 8 months, from 7-15 months of 
age, showed significant A-lowering effect with indomethacin 
alone [165]. These authors suggested that the effect was due to 
inhibition of NFB as cells deficient in NFB activity did not show 
the same response. Certain NSAIDs also exert anti-inflammatory 
activity through activation of the nuclear hormone receptor class of 
transcription factors PPAR [99]. PPAR- belongs to this group of 
nuclear receptors that include PPAR- and PPAR-, which control 
lipid and glucose metabolism, energy levels, monocyte differentia-
tion and inflammatory responses. As mentioned in a previous sec-
tion, natural ligands for PPAR- include certain COX and lipoxy-
genase metabolites, but of the NSAIDs, indomethacin has highest 
affinity and selectivity for PPAR-, with diclofenac, ibuprofen, 
flufenamic acid having lower affinities. PPAR can function through 
several mechanisms, including formation of heterodimers with 
retinoid-x-receptors [166]; these complexes bind to PPRE and acti-
vate transcription of certain genes. Inhibition of inflammatory proc-
esses is believed to occur by a mechanism of receptor-dependent 
transrepression, whereby activated PPAR- interacts with other 
transcription factors or transcriptional co-activators, to prevent the 
activation of inflammatory-associated transcription factors such as 
NFB, STAT-1, C/EBP and AP-1 from activating inflammatory 
gene expression [60]. 
Thiazolidinediones 
  Thiazolidinediones, which are prescribed for the treatment of 
type 2 diabetes to increase insulin sensitivity, are PPAR agonists. 
Agents under investigation as potential AD therapeutics include 
pioglitazone, rosiglitazone, troglitazone and ciglitazone, which also 
act as agonists for PPAR-, but with lower degrees of affinity. 
However, they can also induce significant anti-inflammatory activ-
ity on microglia and macrophages through this pathway. PPAR-
agonists ibuprofen, indomethacin, pioglitazone, ciglitazone, and 
15d-PGJ2 were effective in preventing toxicity to cultured neurons 
from media of A-stimulated monocytes or microglia [31]. Treat-
ment of murine microglia and astrocytes with 15d-PGJ2, rosiglita-
zone, pioglitazone, or ciglitazone reduced secretion of nitric oxide, 
TNF-, IL-1, IL-6 and MCP-1, with the natural ligand 15d-PGJ2
being more effective than the thiazolidinediones [164]. Two studies 
using a rodent model of focal cerebral ischemia demonstrated that 
pioglitazone [109] and rosiglitazone [198] have significant acute 
neuroprotective activities. Treatment of lesioned animals down-
regulated microglial activation, reduced levels of inflammatory 
cytokine synthesis, and reduced infarct volumes in both studies. 
Treatment of 10 month-old APPV717I transgenic mice with ibupro-
fen or pioglitazone for only 7 days reduced numbers of activated 
microglia and astrocytes in cortex and hippocampus. These mice 
also showed significant reduction in COX-2 and iNOS mRNA, 
BACE-1 mRNA and protein levels, and reduction in area occupied 
and staining intensity of A(42) plaques. Pioglitazone-treated ani-
mals showed a 27% reduction in levels of soluble A (42) [70]. 
Anti-inflammatory properties for PPAR- ligands on expression of 
myeloperoxidase (MPO) mRNA were shown in granulocyte-
macrophage colony stimulating factor (GM-CSF) treated human 
macrophages and macrophages from MPO expressing mice, though 
these same agents had a stimulatory effect on MPO expression 
when applied to macrophage colony stimulating factor (M-CSF) 
treated macrophages [95]. A role in AD for MPO, an enzyme se-
creted by phagocytic cells that catalyzes the production of the po-
tent pro-oxidant hypochlorous acid from hydrogen peroxide, has 
been suggested as it colocalizes with plaques and plaque-associated 
microglia in AD brains, and can be expressed by Astimulated 
microglia in vitro [140]. Aberrant induction of MPO in AD brains 
Fig. (3). Potential targets that an “ideal AD therapeutic agent” might modulate to reduce the progression of AD pathology.236    Current Neuropharmacology, 2007, Vol. 5, No. 4 Walker and Lue 
has the potential to contribute to oxidative stress. Two studies have 
shown that polymorphisms in the promoter gene of MPO that alter 
its levels of expression were more abundant in female AD patients 
[140], or those showing cognitive decline [135]. 
  A clinical trial with rosiglitazone was carried out for 24 weeks 
on mild to moderate AD patients. Overall there was no significant 
improvement in treated patients using the ADAS-Cog test, though it 
was shown that there was a significantly different response to the 
drug depending on whether the subject possessed an apoE 4 allele 
[142]. ApoE 4 positive patients continued to show cognitive de-
cline, while apoE 4 negative patients showed slight improvement. 
Polyphenolic Anti-Oxidants 
Curcumin 
  There has been much attention on the yellow curry spice cur-
cumin as a therapeutic agent for AD [9,11,30,101]. When one con-
siders the properties of a hypothetical ideal agent for treating AD 
(Fig. 3), curcumin has many features that meet these requirements. 
Curcumin, an extract of turmeric, is a non-flavonoid polyphenol 
and has been widely used as a safe food additive for many centu-
ries, particularly in India. It has been reported that AD incidence is 
significantly lower in Asian-Indian populations [25], who use this 
spice extensively in food. The biochemical pathways affected by 
this agent are extensive, and many of these could be of significance 
in inhibiting AD pathological changes. Curcumin has identified 
anti-inflammatory properties due to inhibiting activation of the 
NFB, AP-1 and STAT inflammatory pathways [30,88,90, 91,161]. 
It also has defined anti-oxidant properties [51,111,137,154,185, 
190], which can be partially due to the induction of anti-oxidant 
defensive genes heme oxygenase-1, glutathione S transferase and 
quinine reductase in oxidatively-stressed neurons [154], and heat 
shock proteins [111]. Other properties relevant to AD include cho-
lesterol-lowering activity [134], iron chelation [86], A aggregation 
inhibiting properties [127,190] and inhibition of expression of 
MMP-1, -3, -9, -14 [91]. In vitro, curcumin inhibited the formation 
of A fibrils and oligomers from A(40) and A(42), and also in-
duced dissociation of preformed fibrils [127,190]. Curcumin re-
versed markers of oxidative stress in brains of mice caused by 
treatment with the dopaminergic neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) [137]; reversal of oxidative 
stress due to traumatic brain injury in rats has been reported [185]. 
A study involving feeding curcumin to transgenic APP (Tg2576) 
mice in their diet for 6 months demonstrated significant reduction 
in A load, and in levels of the proinflammatory cytokine IL-1
and numbers of activated microglia and reactive astrocytes [101]. A 
more recent study demonstrated that curcumin fed orally to aged 
Tg2576 mice for 5 months reduced A levels and plaque load 
[190]. It was also shown in this study that curcumin could be local-
ized to cerebral plaques. Administration of curcumin to aged rats 
injected intracerebrally with A reduced oxidative damage, mem-
ory deficits and synaptophysin loss [30,52]. Clinical trials spon-
sored by the National Institutes of Health on the effectiveness of 
curcumin as a treatment for AD are underway [2,141]. It is not clear 
whether the anti-amyloid properties of curcumin are more signifi-
cant than the anti-inflammatory or anti-oxidant properties, but hav-
ing a combination of all should be beneficial in inhibiting different 
pathological processes. 
Resveratrol 
  Resveratrol is the principal non-flavonoid polyphenol found in 
grapes and red wine and, similar to curcumin, possesses a range of 
pharmacological properties including anti-oxidation, anti-inflam-
mation, neuroprotection and inhibition of A aggregation [7,112, 
143,153,158]. Both compounds have similar chemical structures. 
Resveratrol has anti-inflammatory properties due to its activation of 
SIRT-1, a class III histone deacetylase; activation of SIRT-1 by 
resveratrol inhibited NF-B signaling by promoting deacetylation 
of a lysine residue on RelA/p65 [194]. Its effectiveness in inhibiting 
A-stimulated microglia-mediated neurotoxicity through this 
mechanism has been demonstrated [27]. Neuronal protection from 
A toxicity, along with promotion of clearance of A peptides, are 
additional properties associated with resveratrol [84,112]. Interest-
ingly, although moderate wine consumption has been associated 
with some protection from AD [138], due to the low amounts of 
resveratrol in red wine, other components have also been impli-
cated. Administration of red wine to transgenic Tg2576 mice was 
effective in lowering plaque load, even though the amount of res-
veratrol present in the wine was considered to be too low to be 
therapeutically effective [180]. 
Statins 
  Statins are widely used to lower circulating levels of cholesterol 
through their activity as HMG-CoA reductase inhibitors and are the 
primary treatment for reducing the risk of coronary heart disease. 
High levels of circulating cholesterol are considered a risk factor 
for developing AD due to its effect on accelerating atherosclerosis 
and vascular inflammation, both of which can promote production 
of A. There has been much interest in the use of statins as preven-
tive therapy for AD, although the epidemiological data are conflict-
ing to their effectiveness at lowering the risk of dementia [87,100, 
196,197]; however, as a recent clinical trial of mild AD patients 
with atorvastatin demonstrated promising improvement in certain 
cognitive parameters, further trials of statins are underway [162]. A 
number of studies have also shown that high cellular cholesterol 
levels promote the secretase pathway of A formation and reduce 
the  -secretase formation of soluble APP (examples [93,129]). 
Treatment of hippocampal and cortical neurons with simvastatin 
and lovastatin reduced amounts of secreted A(40) and A(42), 
while treatment of guinea pigs with simvastatin reduced cerebral 
and CSF levels of A(40) and A(42) [45]. 
  There are now well characterized anti-inflammatory properties 
for statins that are distinct from their cholesterol-lowering proper-
ties. These effects include lowering circulating levels of C-reactive 
protein [24], reducing A-stimulated expression of IL-1 and iNOS 
in cultured macrophages or microglia [32], and reducing expression 
of IL-6 by rodent microglia [102]. 
  Lovastatin, simvastatin, pravastatin and atorvastatin were all 
shown to have significant activity of lowering expression of mye-
loperoxidase (MPO) mRNA expression by human and murine 
macrophages, adding evidence for the anti-inflammatory properties 
of these agents [95]. In addition, simvastatin lowered MPO mRNA 
and enzyme activity even after 1 day in human MPO overexpress-
ing transgenic mice fed drug for 1- 21 days [95].  
  Lovastatin was effective in reducing the severity of EAE 
through reduction in the number of infiltrating T cells and mono-
cytes and reduced secretion of inflammatory cytokines [122]; one 
mechanism appeared to be the reduction of endothelial cell adhe-
sion molecules through inhibition by lovastatin of the phosphoi-
nositide 3 kinase-Akt (protein kinase B)-NFB pathways. 
  Differences were also seen in statin effectiveness in AD mice 
models. One study showed that lovastatin and pravastatin lowered 
A levels in TgCRND8 mice [26], while lovastatin increased A
levels in the brains of female Tg2576 mice, but not male animals 
[128]. Treatment of non-transgenic mice with atorvastatin, simvas-
tatin, or lovastatin lowered endogenous levels of A 40 and 42 [19]. 
Antibiotics 
Minocycline 
  Minocycline is a tetracycline family antibiotic widely pre-
scribed for treating acne skin condition, but also for respiratory and 
neurological infections. However, its other identified anti-inflam-
matory and neuroprotective properties have indicated its possible 
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cycline was effective in reducing inflammatory cytokines IL-1,
IL-6, and TNF levels in an AD transgenic mouse model, and 
improving cognitive performance though not reducing A levels 
[157]. Also, minocycline reduced IL-6 and TNF- production by 
A-stimulated human microglia [44]; this study also demonstrated 
that minocycline in vitro could inhibit A aggregation. Minocycline 
has shown activity as a neuroprotective agent through inhibition of 
microglial activation in a number of animal disease models of neu-
rodegeneration or neuronal damage. Minocycline slowed disease 
progression in a transgenic model of amyotrophic lateral sclerosis 
[94]. In a model of spinal cord injury, animals administered mino-
cycline showed reduced neuronal apoptosis, reduced amounts of 
caspase-3, reduced microgliosis and increased functional recovery 
[48]; one suggested mechanism of action was reduced TNF- pro-
duction by microglia. In three different PD animal models of dopa-
minergic cell loss, induced by thrombin [28], paraquat [136], or 
MPTP [186], administration of minocycline inhibited microglia 
activation, and reduced free radical production by inhibiting the 
microglial NADPH oxidase respiratory, iNOS and cytokine produc-
tion, which resulted in significant reduction in the loss of dopa-
minergic neurons. 
Dapsone 
  Interest in the anti-leprosy antibiotic dapsone (4,4'-diamino-
diphenylsulfone) as an AD therapy came from initial observations 
of lower incidence of AD in a population of Japanese leprosy pa-
tients, who had been treated for many years with this or similar 
anti-leprosy antibiotics [115]. Pathological examination of brains of 
leprosy patients indicated significantly fewer amyloid plaques than 
in age-matched controls [79,121], though the numbers of NFTs 
were either unchanged or increased; however, other studies did not 
confirm these findings [65,92]. Dapsone was not effective in lower-
ing production of A(42) in an in vitro assay [43]. An additional 
mechanism of action for dapsone has been proposed, besides its 
antibiotic properties, namely as an anti-inflammatory. Dapsone has 
significant anti-inflammatory properties as an inhibitor of the en-
zyme myeloperoxidase (MPO) [89,173], but a small clinical trial of 
dapsone in AD patients was unsuccessful [79]. 
Neuro-Receptor Modulators 
Nicotine 
  Smoking is a significant risk factor for the development of AD 
[3,105], likely due to the effects of the many toxic components of 
cigarette smoke (e.g. carbon monoxide, phenols, formaldehyde, 
benzene etc) on the vasculature, and can promote atherosclerosis, 
oxidative stress and hypertension, all risk factors for AD. However, 
nicotine alone has many potential therapeutic properties. Nicotine is 
a potent ligand for a large family of NAChR that are expressed in 
brain and the peripheral nervous system. Tg 2576 transgenic mice 
administered acute and chronic doses of nicotine showed signifi-
cantly less accumulation or load of A in their brains [67,125]; this 
effect was not replicated in a different triple transgenic (APP/tau) 
mouse model [126], where non-significant changes in A levels 
were detected in treated animals, and where nicotine increased the 
proportion of phosphorylated tau. However, recently a significant 
reduction of A(40) and A(42), both soluble and insoluble forms, 
was demonstrated in APP(V717)L transgenic mice administered 
nicotine for 5 months from 9 to 14 months of age. Accompanying 
these findings was the demonstration of significant reduction of 
levels of activated NFB and MAPK pathway components. Inhibi-
tion of these pathways resulted in downregulation of expression of 
apoptosis and cell cycle genes, and reduced amounts of the inflam-
matory-associated iNOS [103]. 
  It has been shown that smokers with AD had significantly less 
soluble and insoluble A(40) and A(42) in hippocampus and tem-
poral cortex brain samples than non-smokers with AD [68], while 
smoking non-demented controls had significantly less soluble 
A(40) and A(42) than non-smoking controls. Although these data 
do not indicate a protective role for smoking in AD, they do suggest 
nicotine as a therapeutic agent for AD warrants further investiga-
tion. This agent can not only inhibit A aggregation and prevent its 
resulting cytotoxicity in vitro [119], but it has significant demon-
strated anti-inflammatory properties. Nicotine in combination with 
galantamine (an acetylcholinesterase inhibitor that has nicotinic 
receptor binding activity) inhibited microglia activation induced by 
HIV gp120 and IFN- [63]; in another study, nicotine or acetylcho-
line significantly inhibited microglia secretion of tumor necrosis 
factor- (TNF-) induced by LPS [160], an effect mediated by 
inhibiting the phosphorylation of p42/44 ERK1/2 and p38 MAPK, 
and attenuated by the NAChR -7 antagonist alpha bungarotoxin. 
Rodent microglia were demonstrated to express NAChR -7
mRNA by RT-PCR [160]. Treatment of rodent microglia with nico-
tine was effective at reducing LPS-induced TNF- secretion, but 
also induced expression of COX-2 and production of PGE2.
NAChR -7 is the receptor mediating the anti-inflammatory effects 
of acetylcholine or nicotine on macrophages, as NAChR -7 defi-
cient mice did not show reduced TNF- secretion in response to 
acetylcholine stimulation [179]. Human monocytes responded to 
nicotine by downregulation of proinflammatory cytokines mediated 
by inhibition of IB phosphorylation and reduced transcription of 
NFB. A role for acetylcholine in mediating the “cholinergic anti-
inflammatory pathway” has been established in the periphery, for 
example bacterial peritonitis in mice was exacerbated if cholinergic 
vagus input was prevented [172], and reduced following nicotine 
administration. An early deficit in acetylcholine has been repeatedly 
demonstrated in AD [50], and is the target for currently prescribed 
acetylcholinesterase drugs to enhance acetylcholine neurotransmis-
sion. These recent data indicate that an acetylcholine deficit may 
contribute to perpetuating the chronic inflammation in AD brains. 
These anti-inflammatory mechanisms could function in human 
brains as we show in Fig. (4) that NAChR-7 mRNA is expressed 
by human microglia derived from postmortem elderly brain, while 
NAChR -4 and NAChR2 are not. 
IMMUNE THERAPY AND AMYLOID SEQUESTRATION 
  The other side of the issue of anti-inflammatory therapy for 
treating AD is the use of immune therapy to induce circulating anti-
bodies to the A peptide so that they can either bind and sequester 
the circulating A from the blood [37], inhibit A fibrillogenesis or 
toxic oligomer formation [53], or bind to plaques in the brain and 
stimulate Fc- receptor mediated phagocytosis by microglia [12]. It 
appears that all three mechanisms could be involved in immune 
clearance of A in mice [120]. The initial findings were that immu-
nizing PDAPP plaque developing mice with aggregated A(42) to 
raise an antibody response to the peptide prevented A deposition if 
mice were immunized at a young age, or aided in the clearance of 
A deposits if mice were immunized at an older age [156]. These 
findings opened up the concepts of immune stimulation as a thera-
peutic approach to AD in a manner that would previously have been 
considered as pathogenic. These findings were widely replicated in 
different transgenic mouse models of AD (reviewed in [59]) with 
either active peptide immunization or passive transfer of antibodies, 
many of which demonstrated improvement in memory tasks in 
immunized mice. Utilizing microglia to phagocytose antibody-
opsonized A through binding to their Fc- immunoglobulin recep-
tors does involve cellular activation with transient increased pro-
duction of free radicals and proinflammatory cytokines [10,106]. 
As microglial activation appears necessary for efficient clearance of 
plaques, this strategy has the potential to exacerbate ongoing neu-
roinflammatory processes before the benefits of A removal are 
realized. 
  Due to the dramatic reduction of A observed in vaccinated 
mice, human clinical trials of the A vaccine (AN1792) on human 
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halted due to meningoencephalitis developing in 18 of 298 vacci-
nated subjects. It appeared that a T-cell mediated autoimmune re-
sponse was responsible for the inflammatory response. Although 
the vaccine trial was terminated, the brains of certain vaccinated 
participants became available for pathological studies. These dem-
onstrated extensive regional plaque clearance [113,124], with evi-
dence for microglial phagocytosis of A; however, tangles were not 
cleared from the cortex and there was persistence of cerebral amy-
loid angiopathy. A recent study of A species in the brains of two 
additional AN1792 vaccinated subjects demonstrated that although 
plaques had been dissolved, the total load of A was not reduced, 
but moved into a soluble oligomeric form. These cases also had 
high levels of A in the white matter, and pronounced deposition of 
A on vessels. These data indicate that antibody-mediated mobili-
zation of A from plaques has the potential to transform A into 
more toxic and inflammatory soluble oligomeric forms [131]. 
AD ANTI-INFLAMMATORY DRUG DISCOVERY 
  Identifying new relevant targets using cell culture models for a 
particular disease provides the basis for drug discovery of poten-
tially specific anti-inflammatory targets for AD inflammation. Our 
laboratory took the approach of global gene expression profiling 
employing human postmortem brain-derived microglia stimulated 
with aggregated/oligomeric A (1-42) to identify all possible genes 
induced by this interaction [177]. The use of human postmortem 
microglia is a well-established model of microglial interactions 
with A plaques for studying the activation of microglia by aggre-
gated A[106,107,140,176]. Our laboratory has shown that block-
ing the A-binding receptor for advanced glycation endproducts 
(RAGE) on Atreated human microglia has significant anti-
inflammatory properties [107]. RAGE, which is upregulated on a 
number of cell types in AD brains including microglia, astrocytes, 
vascular cells and neurons, is currently a drug target for AD, and a 
number of other vascular and inflammatory diseases [75]. We have 
also used an expression profiling approach, the simultaneous induc-
tion by microglia of multiple inflammatory pathways was demon-
strated; these included a range of inflammatory cytokines (e.g. IL-
1, IL-6) chemokines (e.g. IL-8, MCP- 1, -2, -3, MIP -1, -1, -2,
-2, -3;), proteases (e.g. MMP -1,, -3, -9, -12), enzymes (e.g. 
COX-2, indoleamine-pyrole 2,3, dioxygenase) and inflammatory 
receptors (e.g. urokinase plasminogen activator receptor and immu-
noglobulin Fc-receptor-IIa) [177]. In this model for inflammation 
in the AD brain, we identified a range of genes whose expressions 
were induced more than 3-fold in all of the 5 separate isolates of 
microglia used in the study. Although the changes in gene expres-
sion by human microglia following activation by A were pre-
dominantly proinflammatory, we also identified a limited number 
of potentially anti-inflammation molecules that were induced in 
parallel. These included IL-1 receptor antagonist, somatostatin re-
ceptor-2, vitamin D receptor, endothelial cell protein C receptor, 
and adenosine 2A receptor. Upregulation of these proteins on mi-
croglia, particularly the anti-inflammatory receptors, as a result of 
A stimulation suggests a potential target for downregulation of the 
inflammation by administering the receptor ligand or agonist. All of 
these targets have been characterized in different inflammatory 
paradigms, but not as potential therapeutic targets for AD. For ex-
ample, somatostatin receptor-2 is the most abundant of the soma-
tostatin receptors expressed by inflammatory cells [42]; activation 
of somatostatin receptors with somatostatin or agonists can down-
regulate proinflammatory cytokine secretion by human macro-
phages, epithelial cells or rodent microglia [8,29,46,169]. In keep-
ing with our hypothesis that an AD drug should have multiple 
therapeutic mechanisms, it was demonstrated that somatostatin 
treated cortical neurons upregulate the expression of the A peptide 
degrading protease neprilysin. A mouse model with a genetic defi-
ciency of somatostatin had reduced neprilysin and increased A
(42) [152]. As somatostatin levels decline in aging and AD brains, 
supplemental therapy for somatostatin is considered a feasible 
therapeutic option [33,39]. We also propose the vitamin D receptor 
as a novel AD inflammatory target. It is a member of the large fam-
ily of nuclear receptor transcription factors and specifically binds 
the micronutrient-derived hormone 1, 25-dihydroxyvitamin D3. 
Vitamin D is an essential factor in stimulating or maintaining bone 
formation; however, this agent has also been shown effective 
  in inhibiting inflammation [69,150,174]. For example, 1, 25-
dihydroxyvitamin D3 treatment of IFN- stimulated macrophage 
inhibited the macrophage respiratory burst and reduced expression 
of a number of IFN- induced inflammatory genes [69]. Also, vita-
min D3 was effective in protecting culture neurons from the toxic 
effects of glutamate or reactive oxygen species [78,167]. In vitro,
vitamin D3 treatment of rats with chronic relapsing EAE was effec-
tive in reducing disease severity by inhibiting microglia and T cells 
activation and iNOS expression [55]. Although use of the active 
agent may not be possible due to the side-effect of hypercalcemia, 
vitamin D agonists lacking these properties, such as elocalitol, have 
anti-inflammatory properties in vivo [132]. 
CONCLUSIONS 
  It is still not possible to conclude if anti-inflammatory treatment 
alone is no longer a valid approach for treating AD. It seems that 
the central focus of pharmaceutical drug development will remain 
on inhibiting A production and aggregation, with anti-inflam-
matory properties of any such agents being a bonus. As discussed, 
there is a large body of experimental data from animal or cell cul-
ture models demonstrating that A or cytokine-activated microglia 
can produce factors that are neurotoxic, epidemiological data show-
ing the protective effect from developing AD of taking NSAIDs, 
pathological studies of postmortem AD brains showing many fea-
tures of inflammation; and that anti-inflammatory drugs are effec-
tive for treating other neurodegenerative diseases or disease models, 
e.g., multiple sclerosis, HIV-associated dementia, PD, ALS, or 
stroke. All of the above suggest (but do not prove) that an inflam-
matory component must be involved in the pathogenesis of AD. It 
is clear that cerebral or peripheral inflammation can be an early 
Fig. (4). Human microglia express mRNA for nicotinic acetylcholine receptor 7. Panel A –Reverse transcription-polymerase chain reaction showing expres-
sion by different isolates of human microglia of 7 nicotinic acetylcholine receptor mRNA (NAChR7) (lanes 1-3). Panels B and C: show that human micro-
glia do not express 2 (NAChR2) or 4 (NAChR4) nicotinic acetylcholine receptor mRNA (lanes 1-3). As positive controls (panels A, B, C: lane 4), cDNA
from a sample of differentiated SH-SY5Y neuronal-like cells showing positive expression of nicotinic acetylcholine receptor 7, 2 and 4.Anti-inflammatory and Immune Therapy for Alzheimer's Disease  Current Neuropharmacology, 2007, Vol. 5, No. 4    239
event in the AD degenerative process, occurring before memory 
loss; however, separating the inflammatory pathology from the 
effects of A on neurotoxicity and neuroinflammation may not be 
possible, or necessary. Many of the NSAIDs that have been shown 
to be effective in protecting against AD in epidemiological studies, 
though not in clinical studies, also have defined A-lowering prop-
erties [14,43,85,182,183]. Although, it has been suggested that the 
effective doses of NSAIDs so as to have A-lowering properties 
were above the physiological doses that can be used to treat pa-
tients, the effect of long-term use of these drugs at lower doses on 
A production in presymptomatic subjects remains to be deter-
mined. Much research is still being carried out on producing and 
testing a modified A vaccine, or testing whether passive immuni-
zation with anti-A antibodies have similar A clearing effects. 
This approach might always have limitations as it is focused on the 
single target of A removal and actually has a proinflammatory 
effect due to the stimulation of microglia to phagocytose antibody-
opsonized plaques. 
  At present, the agent curcumin, which ironically has been avail-
able for centuries as a food additive, appears to have the great po-
tential, based on convincing experimental data of its efficacy as an 
anti-oxidant, anti-inflammatory and anti-amyloid agent, to be an 
effective AD therapeutic agent. The phase II clinical trial of curcu-
min is scheduled to be completed by December 2007 [2]. 
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ABBREVIATIONS 
A =  Amyloid  beta 
AP-1 =  Activator  Protein-1 
APP  =  Amyloid precursor protein 
APOE =  Apolipoprotein  E 
AD =  Alzheimer’s  disease 
BACE-1  =  Beta-Site APP-Cleaving Enzyme 1 
COX =  Cyclooxygenase 
EAE  =  Experimental Autoimmune Encephalomyelitis 
HIV  =  Human Immunodeficiency Virus 
IFN- =  Interferon  gamma 
IL =  Interleukin 
iNOS  =  Inducible Nitric Oxide Synthase 
LPS =  Lipopolysaccharide 
MAPK  =  Mitogen-Activated Protein Kinase 
MCP  =  Monocycte Chemoattractant Protein 
MMP =  Matrix  Metalloproteinase 
MIP  =  Macrophage Inflammatory Protein 
NAChR  =  Neuronal Acetylcholine Receptor 
NFTs =  Neurofibrillary  tangles 
NFB =  Nuclear  Factor  B
NSAIDS  =  Non-steroidal Anti-inflammatory Drugs 
PD =  Parkinson’s  disease 
PG =  Prostaglandin 
PPAR =  Peroxisome  proliferator-activated  receptor 
STAT  =  Signal Transducer and Activators of Transcription 
TNF  =  Tumor Necrosis Factor 
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